**Author details**

*Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications*

Natural Science Foundation of China (No. 81974502 and 81671293).

There is no potential conflict of interest.

CNS central nervous system AD Alzheimer's disease PD Parkinson's disease AED antiepileptic drug BBB blood–brain barrier Pgp P-glycoprotein


GABAA gamma-aminobutyric acid

ICH intracerebral hemorrhage SOD superoxide dismutase LKB1 liver kinase B1

5-HT 5-hydroxytryptamine LID L-DOPA-induced dyskinesia βAR β-adrenergic receptors AChE acetylcholinesterase CGNs cerebellar granule neurons ARBs angiotensin receptor blockers

NMDA N-methyl-D-aspartate

Ang II angiotensin II

BDNF brain-derived neurotrophic factors

MS multiple sclerosis TBI traumatic brain injury TrkB tyrosine kinase receptor B

The authors apologize to all the investigators whose work cannot be cited in this paper due to space constraint. This work was partly supported by the National


AMPK adenosine 5′-monophosphate (AMP)-activated protein kinase

**Acknowledgements**

**Conflict of interest**

**Abbreviations**

NKCC1 Na+

**88**

Xiao-Yuan Mao1,2,3,4

1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China

2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China

3 Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China

4 National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P.R. China

\*Address all correspondence to: xiaoyuanm@csu.edu.cn; maoxiaoyuan2011@163.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
